OPKO Health (OPK) Reports Positive Top Line Results from Rayaldee Phase 3 Trial
- Dow, S&P 500 end with gains up after bumpy week, but Nike drags
- Over $100 Billion Wiped Off: Bitcoin (BTC) Price Falls As China's Central Bank Vows to Ban Cryptocurrency Trading
- Nike (NKE) Stock Falls On a Revenue Miss and Slashed FY Sales Outlook, Analysts Bullish Despite NT Supply Chain Challenges
- Oil hits highest in almost 3 years as supply tightens
- Here's Why Meredith (MDP) Stock Price Soared 18% in After Hours
OPKO Health, Inc. (NYSE: OPK), announced successful top-line results from the first pivotal phase 3 trial of Rayaldee™. This trial is one of two identical randomized, double-blind, placebo-controlled, multi-site studies intended to establish the safety and efficacy of Rayaldee as a new treatment for secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. Both trials are the subject of a Special Protocol Assessment (SPA) established with the United States (U.S.) Food and Drug Administration (FDA) in August 2012.
“Top-line data from this study demonstrate that Rayaldee effectively controls secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease by correcting vitamin D insufficiency,” stated Joel Z. Melnick, MD, Vice President of Clinical Research and Development for OPKO’s Renal Division. “Rayaldee was equally effective in both disease stages, indicating that this new therapy is appropriate even for patients with minimal functioning kidney mass.”
This trial involved 213 adult patients recruited from 39 sites throughout the U.S. Patients were stratified by CKD stage and randomized in a 2:1 fashion to receive six months of treatment with either Rayaldee or placebo. On enrollment, all patients exhibited vitamin D insufficiency which was corrected in 96% of patients treated with Rayaldee.
The completed trial successfully met all primary efficacy and safety endpoints. The primary efficacy endpoint was a responder analysis in which “responder” was defined as any treated subject who demonstrated an average 30% decrease in plasma parathyroid hormone (PTH) from pre-treatment baseline during the last six weeks of the treatment period. A significantly higher response rate (p<0.001) was observed with Rayaldee which steadily increased with treatment duration. The response rate with Rayaldee was similar in CKD stages 3 and 4. Safety and tolerability data were comparable in both treatment groups.
“Rayaldee is designed to fill a void in the treatment armamentarium of nephrologists and endocrinologists who care for pre-dialysis chronic kidney disease patients,” commented Dr. Charles W. Bishop, CEO of OPKO’s Renal Division. “Controlled trials have shown that over-the-counter and prescription vitamin D supplements are ineffective in treating SHPT in these patients and are, at best, unreliable in correcting vitamin D insufficiency. On the other hand, vitamin D hormone drugs can effectively treat SHPT but, due to high potency, often oversuppress PTH, increasing the risk of adynamic bone disease and vascular calcification. These hormone drugs are entirely ineffective in treating vitamin D insufficiency, the underlying cause of SHPT in most pre-dialysis patients. Rayaldee addresses a long-standing unmet need to safely control SHPT by reliably correcting vitamin D insufficiency.”
“Physicians will embrace a product that does what we want, namely, treat vitamin D insufficiency and gradually correct elevated PTH, without safety concerns,” stated David A. Bushinsky, MD, Chief, Nephrology Division, University of Rochester Medical Center. “Data from this first pivotal trial indicate that Rayaldee may be such a product, and I look forward to confirmation from the second identical trial.”
Top-line data from the second, identical pivotal phase 3 trial are expected to be available in September 2014.
Patients completing the two pivotal trials are being treated, at their election, for an additional 6 months with Rayaldee during an ongoing open-label extension study. Enrollment in this extension study surpassed the targeted level of 270 patients by May 2014 and 141 patients have completed participation.
“Rayaldee is the lead candidate in a growing portfolio of products that OPKO is developing in its Renal Division for global commercialization,” explained Dr. Phillip Frost, Chairman and CEO of OPKO Health. “Rayaldee provides an excellent solution to the problem of secondary hyperparathyroidism associated with vitamin D insufficiency for more than 4 million CKD patients in the U.S. and many more elsewhere.”
A New Drug Application (NDA) submission to the U.S. FDA is on track for the end of 2014.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OPKO Health (OPK) and Pfizer (PFE) Extend U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency
- Capricor Therapeutics (CAPR) Reports Positive Phase 2 HOPE-2 Trial Data in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002
- CVS Health (CVS) Announces Pfizer-BioNTech Booster Shot is Available to Eligible Populations
Create E-mail Alert Related CategoriesCorporate News, FDA, Hot Corp. News, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!